EB²¡¶¾£¨Epstein-Barr virus£¬EBV£©ÊÇË«Á´DNA²¡¶¾£¬ÈËȺÆÕ±éÒ׸С£Í¨³£EBVµÄÔ·¢Ñ¬È¾ÊÇ·ÇÖÂÃüµÄ£¬µ«²¡¶¾µÄÔÙ¼¤»î¿ÉÒÔµ¼Ö¼«ÉÙÊýѬȾÕß·ºÆðϸ°ûÒò×ӷ籩¡¢ÊÉѪϸ°ûÁܰÍ×éÖ¯ÔöÉúÖ¢£¨hemophagocytic lymphohistiocytosis£¬HLH£©¡¢ EBVÏà¹ØÁܰÍ×éÖ¯ÔöÉúÐÔ¼²²¡£¨EBV-associated lymphoproliferative disorders£¬EBV-LPD£©£¬ÉõÖÁ½øÕ¹Îª¶ñÐÔÁܰÍÁöºÍ°×Ѫ²¡¡£
ÂýÐԻÐÔEBVѬȾ(CAEBV)ÊÇÓÉEBVÁ¬ÐøÑ¬È¾TÁܰÍϸ°û»ò×ÔȻɱÉËNKϸ°ûÒýÆðµÄÒ»ÖÖÁܰÍÔöÉúÐÔ¼²²¡£¬Ö÷ÒªÌåÏÖΪÁܰÍϸ°ûÔöÉúºÍEBV×éÖ¯½þÈó¡£²¿ÃÅ»¼¶ù¿ÉÉú³¤ÎªÑ×ÐÔϸ°ûÒò×ӷ籩ºÍÊÉѪϸ°ûÐÔÁܰÍ×é֯ϸ°ûÔöÉúÖ¢(HLH)¡£CAEBVµÄÁÙ´²²¡³ÌÊÇÒìÖÊÐԵģ¬Ä¿Ç°È±Ö®ÓÐЧµÄÖÎÁƼÆÄ±¡£ËäÈ»ÌÇÆ¤Öʼ¤ËØºÍÆäËûÃâÒßÒÖÖÆ¼Á¿ÉÒÔÔÝʱ¸ÄÉÆÁÙ´²²¡³Ì£¬»¼Õß×îÖÕÈÔÐè½øÐÐÔìѪ¸Éϸ°ûÒÆÖ²(HSCT)¡£Èç¹ûûÓÐÓÐЧµÄÖÎÁÆ£¬CAEBV¿ÉÄÜ»áÉú³¤ÎªÁܰÍÁö»òÑÏÖØµÄÈ«ÉíÐÔÑ×Ö¢£¬ÉõÖÁËÀÍö¡£ÏÈǰµÄÑо¿±íÃ÷tϸ°ûÐÍCAEBV»¼ÕߵIJ¡³Ì¸ü¾ßÇÖÏ®ÐÔ£¬Éú´æÆÚÃ÷ÏԽ϶̡£NKϸ°ûÐÍCAEBV»¼Õßͨ³£Ö¢×´½ÏÇᣬÁÙ´²Ô¤ºó½ÏºÃ¡£
±¾ÎÄ̽ÌÖÁËС¶ùCAEBV»¼ÕßÍâÖÜѪEBVѬȾÁܰÍϸ°ûÑÇÐ͵ÄÁÙ´²Ìص㣬ּÔÚ·ÖÎöEBVѬȾϸ°ûÀàÐÍÓëÁÙ´²ÌåÏֵĹØÏµ£¬ÔçÆÚ·¢ÏÖÎ£ÖØ»¼¶ù£¬½ÓÄÉÓÐЧÖÎÁÆ¡£
ÒªÁìѧ
½ÓÄÉÁ÷ʽϸ°ûÊõºÍ¶¨Á¿¾ÛºÏøÁ´·´Ó³(QPCR)¼ì²â2017Äê7ÔÂÖÁ2022Äê7ÔÂCAEBV»¼ÕßÍâÖÜѪEBVѬȾCD4+Tϸ°û¡¢CD8+Tϸ°ûºÍCD56+×ÔȻɱÉË(NK)ϸ°ûµÄˮƽ¡£
½á ÂÛ
¹²¶Ô112ÀýCAEBV»¼¶ù½øÐÐÁËÆÀ¹À£¬ÆäÖÐCD4+ÐÍ44Àý£¬CD8+ÐÍ21Àý£¬CD56+ÐÍ47Àý¡£CD8+tϸ°ûÐÍ»¼Õß·ºÆðƤÕîµÄƵÂÊÏÔÖø¸ßÓÚCD4tϸ°ûÐÍ»¼Õߣ¬¶ø¸ÎÖ×´óÔÚCD4+ϸ°ûÐÍ»¼ÕßÖиüΪ³£¼û¡£×ÜÌå¶øÑÔ£¬CD8+ϸ°û»¼ÕßµÄ×ÜÉú´æÂÊ×îµÍ£¨P =0.017£©¡£»¯ÁÆÁªºÏÔìѪ¸Éϸ°ûÒÆÖ²(HSCT)»¼ÕßÔ¤ºó½ÏºÃ(P =0.001)¡£ÔÚ¶àÒòËØ·ÖÎöÖÐÆ¤Õî¡¢ÊÉѪϸ°ûÐÔÁܰÍ×é֯ϸ°ûÔö¶àÖ¢¡¢CD8+ϸ°ûÐÍ¡¢ÖÎÁƺóѪ½¬EBV-DNAδϽµÊÇÔ¤ºó²»Á¼µÄ¶ÀÁ¢Ö¸±ê£¨PÖµ·ÖÔòΪ0.002¡¢ 0.024¡¢ 0.022¡¢ 0.0121£©¡£
½á¹û 1 Èë×黼ÕßµÄÁÙ´²ÌØÕ÷
¹²ÄÉÈë112ÀýCAEBV»¼¶ù£¬ÆäÖÐÄÐͯ60Àý£¬Å®Í¯52Àý(ÄÐÅ®±ÈÀý1.15:1)£¬ÖÐλÄêÁä6.51ÂÞ(·¶Î§0.58,14.33)¡£ÔÚ±¾´ÎµÄÑо¿ÖУ¬ËùÓл¼Õß¶¼Ã»ÓÐDZÔڵIJ¡ÀíÔö¼Ó¶ÔEBV¼²²¡µÄÒ׸ÐÐÔ¡£106Àý»¼ÕßÓз¢ÉÕ£¬83ÀýÓÐÁÜͶºÏÖ×´ó£¬78ÀýÓиÎÖ×´ó£¬71ÀýÓÐÆ¢Ö×´ó¡£42Àý»¼¶ù·ºÆð¹ÇËèÊÉѪϸ°ûÔö¶à£¬56Àý»¼¶ùºÏ¿ªHLH¡£Èë×é¶ùͯѪ½¬EBV-DNAÔØÁ¿Îª1.665 X103(5.00X102-8.93X106)copies/ml£¬¶øÈ«ÑªEBV-DNAÔØÁ¿Îª3.29X106(5.00X102-4.12x107)copies/mL¡£
½á¹û 2 ebvѬȾµÄϸ°ûÑÇȺ
½ÓÄÉÁ÷ʽϸ°ûÊõºÍgPCR¼ì²â112Àý»¼¶ùebvѬȾÁܰÍϸ°ûÑÇÐÍ¡£½á¹ûÏÔʾ£¬84Àý»¼ÕßTϸ°û¡¢Bϸ°ûºÍNKϸ°û¾ùÓÐEBVѬȾ£¬12Àý»¼ÕßTϸ°ûºÍNKϸ°û¾ùÓÐѬȾ£¬4Àý»¼Õß½öѬȾTÁܰÍϸ°û£¬5Àý»¼Õß½öѬȾNKϸ°û¡£Æ¾¾ÝEBV-DNAÔÚÁܰÍϸ°ûÖеÄ×î¸ßÔØÁ¿£¬CD4+ϸ°ûÐÍ¡¢CD8+ϸ°ûÐͺÍCD56+ NKϸ°ûÐ͵ÄÊýÁ¿·Ö±ðΪ44¡¢21ºÍ47¡£¶ÔËùÓл¼Õß½øÐÐÁ˲îÒ첿λµÄ×éÖ¯»î¼ì£º96Àý¹ÇËè¡¢70ÀýÁÜͶºÏ¡¢14ÀýƤ·ô¡¢5Àý賦µÀ¡¢4Àý¸ÎÔàºÍ3ÀýÖ×Áö(1ÀýÔÚ±ÇÑÊ¡¢1ÀýÔÚ´½²¿ºÍ1ÀýÔÚ¿ïÖÜÇøÓò)¡£»î¼ì½á¹ûÓëebvÏà¹ØµÄT/NKϸ°ûÁܰÍÔöÉúÐÔ¼²²¡±íÐÍÒ»Ö¡£ÎÄÕ·¢ÏÖCD8+ϸ°ûÐÍ»¼Õ߯¤Õî·¢ÉúÂÊÃ÷ÏÔ¸ßÓÚCD4+ϸ°ûÐÍ»¼Õߣ¬¸ÎÖ×´ó·¢ÉúÂÊÔò¸ü¸ß¡£²îÒìÑÇÐÍ»¼Õß²¡Àí·Ö¼¶²îÒìÎÞͳ¼ÆÑ§ÒâÒå(P= 0.05)¡£ÎÒÃÇ»¹·ÖÎöÁËѪÇåϸ°ûÒò×ÓIFN-Y¡¢TNF-¡¢IL-2¡¢IL-4¡¢L-6ºÍIL-10µÄˮƽ¡£ÑªÇåϸ°ûÒò×ÓˮƽÔÚCAEBV²îÒ첡Àí·Ö¼¶¼°²îÒìÁܰÍϸ°ûÑÇÐͼäÎÞÏÔÆÕ²îÒì(P> 0.05)¡£
½á¹û 3 Ô¤ºó·ÖÎö
סԺºó£¬½«112Àý»¼Õ߯¾¾ÝÖÎÁÆÒªÁì·ÖΪ2×飺»¯ÁÆ×é79Àý(63Àý½øÒ»²½ÐÐHSCT)¹ûÓÃDEP/L-DEPÖÎÁÆ£»ÁíÒ»ÖÎÁÆ×é33Àý»¼Õß½ö½ÓÊܼ¤ËغͿ¹²¡¶¾ÖÎÁÆ¡£½ØÖÁ2022Äê12ÔÂ31ÈÕµÄ×îºóÒ»´ÎËæ·Ã£¬15Ãû»¼ÕßËÀÍö£¬ÆäÖÐ6ÈËËÀÓÚÒÆÖ²ºó²¢·¢Ö¢£¬9ÈËËÀÓÚ¼²²¡½øÕ¹(1ÈËÔÚHSCTºóÉú³¤Îª»î¶¯ÐÔHLH¡£8ÈËδ½øÐÐHSCT)¡£ÖÐÎ»Ëæ·Ãʱ¼äΪ3.36(0.15- 5.48)Äê¡£3Äê×ÜÉú´æÂÊ(OS)Ϊ79.3%(SD 6.1%)(ÏÂͼA)¡£HLH»¼¶ù3ÄêOSÂÊÏÔÖøµÍÓÚÎÞHLH»¼¶ù(67.3%SD 10.7%] vs 91.3%[SD 5.3%]£¬P= 0.014;ÏÂͼ B)¡£È»¶ø£¬½ÓÊÜ»òδ½ÓÊÜHSCTµÄ»¼ÕßÎÞÏÔÕß²îÒì(84.5%[SD 6.2%] vs 72.1%[SD 10.2%]£¬P = 0.166;ÏÂͼC)¡£III¼¶»¼ÕßµÄ3ÄêOSÂʵÍÓÚI¼¶»¼Õß(50.0%[SD 35.4%] vs 88.0%[SD5.2%]£¬ P= 0.020)(ÏÂͼD)¡£
ÔÚ±ÈÁ¦²îÒìÁܰÍϸ°ûÑÇÐÍʱ£¬±¾ÎÄ·¢ÏÖCD8+ϸ°ûÐÍ»¼ÕßÓëCD4+ϸ°ûÐͺÍCD56 NK+ϸ°ûÐÍ»¼ÕßÏà±È£¬3ÄêOSÂÊ×îµÍ(80.9%[SD 11.4%] vs 53.2%[SD 14.6%] vs 91.3% [SD]4.2%]£¬ p=.017;ÏÂͼA)¡£´ËÍ⣬HLH»¼ÕßµÄ3ÄêOSÂÊÔÚCD8+ϸ°ûÀàÐÍÉÏÒ²µÍÓÚÎÞHLH»¼Õß(37.0%[SD 18.1%] vs 75.0%[SD 21.7%], P = 0.045;ÏÂͼB-D)¡£
±¾ÎÄ»¹·ÖÎöÁ˲îÒìÖÎÁÆÒªÁì¶ÔCAEBVµÄÔ¤ºó¡£»¯ÁÆ×éºÍÆäËûÖÎÁÆ×éµÄ3ÄêOSÂÊûÓвîÒ죬¶ø½ÓÊÜ»¯ÁƲ¢½øÒ»²½½øÐÐHSCTµÄ»¼ÕßµÄ3ÄêOSÂʸßÓÚδ½øÐÐHSCTµÄ»¼Õß(ÏÂͼAºÍB)¡£ÎÞÂÛÊÇ·ñ»¯Áƺó½øÐÐHSCT£¬CD8tϸ°ûÀàÐÍ»¼½«µÄ3ÄêOS×îµÍ(ÏÂͼCºÍD)¡£Ïà±È֮ϣ¬ÆäËûÖÎÁÆ×é²îÒìÑÇÐÍÖ®¼äµÄOSÂÊÎÞ²îÒì(ÏÂͼE)¡£
5Àý»¼Õß½öÔÚCD56+ NKϸ°ûÖз¢ÉúEBVѬȾ£¬ÆäÖÐ3Àý½ÓÊÜ»¯ÁƺÍHSCT£¬¸Ã5Àý»¼Õß¾ù´æ»î¡£
ÌÖ ÂÛ
CAEBVµÄ²îÒìÁÙ´²ÌåÏÖ¿ÉÄÜÓë²îÒìµÄÁܰÍϸ°ûÑÇÐÍÓйء£Ä¾Ñо¿»¼ÕßѬȾ²¿Î»ÒÔTÁܰÍϸ°ûΪÖ÷£¬Õ¼58.0%¡£ÆäÖÐCD4+Tϸ°ûѬȾռ67.7%¡£ÕâÓëÒÔÍùµÄÑо¿Ò»Ö£¬CAEBVµÄÒì³£Tϸ°ûȺͨ³£ÎªCD4+¡£±¾Ñо¿±íÃ÷£¬CD8+Tϸ°ûÐÍ»¼Õ߸üÈÝÒ×·ºÆðƤÕ¶øCD4+tϸ°ûÐÍ»¼½«¸üÈÝÒ×·ºÆð¸ÎÖ×´ó¡£±¾ÎÄÖ¤Ã÷ÔÚ²îÒìebvѬȾµÄCAEBVÁܰÍϸ°ûÑÇÐÍÖУ¬ÕâЩϸ°ûÒò×ӵĸßˮƽÓ벡Àí·Ö¼¶Ö®¼äûÓйØÏµ¡£ebvÏà¹Ø¼²²¡¿ÉÄÜÓвîÒìµÄÉú³¤¹ý³Ì¡£
²Î¿¼ÎÄÏ×
Wei A, Ou W, Zhao Y, Ma H, Zhang L, Lian H, Zhao X, Zhang Q, Wang D, Li Z, Wang T, Zhang R. Clinical characteristics of peripheral lymphocyte subtypes in chronic active Epstein-Barr virus infection. J Infect Dis. 2023 Oct 3:jiad435. doi: 10.1093/infdis/jiad435. Epub ahead of print. PMID: 37787605.